Abstract
Two new oxazolidinones were tested to determine interpretive susceptibility testing criteria for MIC and disk diffusion methods. Commercial lots of linezolid (formerly U-100766) and eperezolid (formerly U-100592) disks containing 30 microg of drug were tested against 728 isolates of bacteria with defined mechanisms of resistance. Results from linezolid were highlighted because of its choice for clinical development. By using preliminary pharmacokinetic data, a tentative susceptibility breakpoint of < or = 4 microg/ml was selected. Corresponding breakpoint zone diameters for linezolid were > or = 21 mm (< or = 4 microg/ml) for susceptibility and < or = 17 mm (> or = 16 microg/ml) for resistance. Regression statistics demonstrated a high correlation coefficient (r > or = 0.98), and absolute categorical agreement between methods was obtained, when staphylococci and enterococci were tested with the cited criteria. When Streptococcus spp. (including S. pneumoniae) were tested, only the susceptibility breakpoint was suggested. Quality control (QC) guidelines for linezolid disk diffusion tests were established by a multilaboratory trial as follows: 27 to 31 mm for Staphylococcus aureus ATCC 25923 and 28 to 34 mm for S. pneumoniae ATCC 49619. More than 95% of all QC results were within these proposed ranges. Although not advanced to clinical trials, eperezolid demonstrated potency comparable to that of linezolid and had identical interpretive testing criteria. These preliminary interpretive criteria and QC limits (accepted by the National Committee for Clinical Laboratory Standards) should be applied to linezolid tests during the clinical-trial phases of oxazolidinone drug development in order to ensure test accuracy and reproducibility.
Full Text
The Full Text of this article is available as a PDF (162.0 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Brumfitt W., Hamilton-Miller J. M. In-vitro microbiological activities of DuP 105 and DuP 721, novel synthetic oxazolidinones. J Antimicrob Chemother. 1988 Jun;21(6):711–720. doi: 10.1093/jac/21.6.711. [DOI] [PubMed] [Google Scholar]
- Cormican M. G., Jones R. N. Emerging resistance to antimicrobial agents in gram-positive bacteria. Enterococci, staphylococci and nonpneumococcal streptococci. Drugs. 1996;51 (Suppl 1):6–12. doi: 10.2165/00003495-199600511-00004. [DOI] [PubMed] [Google Scholar]
- Daly J. S., Eliopoulos G. M., Reiszner E., Moellering R. C., Jr Activity and mechanism of action of DuP 105 and DuP 721, new oxazolidinone compounds. J Antimicrob Chemother. 1988 Jun;21(6):721–730. doi: 10.1093/jac/21.6.721. [DOI] [PubMed] [Google Scholar]
- Eliopoulos G. M., Wennersten C. B., Gold H. S., Moellering R. C., Jr In vitro activities in new oxazolidinone antimicrobial agents against enterococci. Antimicrob Agents Chemother. 1996 Jul;40(7):1745–1747. doi: 10.1128/aac.40.7.1745. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Jones R. N., Johnson D. M., Erwin M. E. In vitro antimicrobial activities and spectra of U-100592 and U-100766, two novel fluorinated oxazolidinones. Antimicrob Agents Chemother. 1996 Mar;40(3):720–726. doi: 10.1128/aac.40.3.720. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Kaatz G. W., Seo S. M. In vitro activities of oxazolidinone compounds U100592 and U100766 against Staphylococcus aureus and Staphylococcus epidermidis. Antimicrob Agents Chemother. 1996 Mar;40(3):799–801. doi: 10.1128/aac.40.3.799. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Mason E. O., Jr, Lamberth L. B., Kaplan S. L. In vitro activities of oxazolidinones U-100592 and U-100766 against penicillin-resistant and cephalosporin-resistant strains of Streptococcus pneumoniae. Antimicrob Agents Chemother. 1996 Apr;40(4):1039–1040. doi: 10.1128/aac.40.4.1039. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Mulazimoglu L., Drenning S. D., Yu V. L. In vitro activities of two novel oxazolidinones (U100592 and U100766), a new fluoroquinolone (trovafloxacin), and dalfopristin-quinupristin against Staphylococcus aureus and Staphylococcus epidermidis. Antimicrob Agents Chemother. 1996 Oct;40(10):2428–2430. doi: 10.1128/aac.40.10.2428. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Peters J., Kondo K. L., Lee R. K., Lin C. K., Inderlied C. B. In-vitro activity of oxazolidinones against Mycobacterium avium complex. J Antimicrob Chemother. 1995 May;35(5):675–679. doi: 10.1093/jac/35.5.675. [DOI] [PubMed] [Google Scholar]
- Poyart C., Pierre C., Quesne G., Pron B., Berche P., Trieu-Cuot P. Emergence of vancomycin resistance in the genus Streptococcus: characterization of a vanB transferable determinant in Streptococcus bovis. Antimicrob Agents Chemother. 1997 Jan;41(1):24–29. doi: 10.1128/aac.41.1.24. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Slee A. M., Wuonola M. A., McRipley R. J., Zajac I., Zawada M. J., Bartholomew P. T., Gregory W. A., Forbes M. Oxazolidinones, a new class of synthetic antibacterial agents: in vitro and in vivo activities of DuP 105 and DuP 721. Antimicrob Agents Chemother. 1987 Nov;31(11):1791–1797. doi: 10.1128/aac.31.11.1791. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Worth S., Erwin M. E., Jones R. N. Quality control guidelines for amoxicillin, amoxicillin-clavulanate, azithromycin, piperacillin-tazobactam, roxithromycin, ticarcillin, ticarcillin-clavulanate, trovafloxacin (CP 99,219), U-100592, and U-100766 for various National Committee for Clinical Laboratory Standards susceptibility testing methods. Results from multicenter trials. Diagn Microbiol Infect Dis. 1996 Feb;24(2):87–91. doi: 10.1016/0732-8893(95)00276-6. [DOI] [PubMed] [Google Scholar]
- Zurenko G. E., Yagi B. H., Schaadt R. D., Allison J. W., Kilburn J. O., Glickman S. E., Hutchinson D. K., Barbachyn M. R., Brickner S. J. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents. Antimicrob Agents Chemother. 1996 Apr;40(4):839–845. doi: 10.1128/aac.40.4.839. [DOI] [PMC free article] [PubMed] [Google Scholar]